Delcath Systems (NASDAQ:DCTH) Earns Buy Rating from Analysts at Craig Hallum

Craig Hallum started coverage on shares of Delcath Systems (NASDAQ:DCTH) in a report released on Friday, Marketbeat.com reports. The brokerage issued a buy rating and a $18.00 price target on the stock.

A number of other research analysts have also recently weighed in on the company. Stephens assumed coverage on Delcath Systems in a research report on Tuesday, May 14th. They issued an overweight rating and a $25.00 price target for the company. StockNews.com upgraded shares of Delcath Systems to a sell rating in a report on Wednesday, March 27th. Finally, HC Wainwright increased their price target on shares of Delcath Systems from $20.00 to $22.00 and gave the company a buy rating in a research report on Wednesday, May 15th. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of Moderate Buy and a consensus target price of $19.83.

Delcath Systems Stock Up 1.7 %

Shares of NASDAQ:DCTH opened at $8.37 on Friday. The company has a 50-day moving average price of $6.83 and a 200 day moving average price of $5.21. Delcath Systems has a 52 week low of $2.25 and a 52 week high of $9.18. The company has a market cap of $232.60 million, a P/E ratio of -3.16 and a beta of 0.60.

Delcath Systems (NASDAQ:DCTH) last released its quarterly earnings data on Tuesday, May 14th. The company reported ($0.43) EPS for the quarter, hitting analysts’ consensus estimates of ($0.43). Delcath Systems had a negative net margin of 1,080.72% and a negative return on equity of 290.07%. The firm had revenue of $3.14 million for the quarter, compared to the consensus estimate of $3.70 million. Analysts expect that Delcath Systems will post -1.31 EPS for the current year.

Hedge Funds Weigh In On Delcath Systems

A number of hedge funds have recently made changes to their positions in DCTH. WealthPlan Investment Management LLC acquired a new position in shares of Delcath Systems during the fourth quarter worth about $73,000. Levin Capital Strategies L.P. raised its holdings in shares of Delcath Systems by 22.5% during the 4th quarter. Levin Capital Strategies L.P. now owns 49,000 shares of the company’s stock valued at $204,000 after buying an additional 9,000 shares during the period. Armistice Capital LLC purchased a new stake in shares of Delcath Systems during the 3rd quarter valued at about $664,000. ADAR1 Capital Management LLC acquired a new position in Delcath Systems during the 4th quarter worth approximately $962,000. Finally, Worth Venture Partners LLC purchased a new position in Delcath Systems in the 4th quarter worth approximately $1,224,000. Hedge funds and other institutional investors own 61.12% of the company’s stock.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.